Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options

Autor:	Andrew Weickhardt, Carole A. Harris, Laurence Eliot Miles Krieger, Jeffrey C. Goh, Anthony M. Joshua, Arun Azad, Andrew Schmidt
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Alpha interferon Angiogenesis Inhibitors urologic and male genital diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Renal cell carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans 030212 general & internal medicine Carcinoma Renal Cell Protein Kinase Inhibitors Everolimus business.industry Sunitinib Australia Cancer General Medicine medicine.disease Prognosis Kidney Neoplasms Clear cell renal cell carcinoma chemistry 030220 oncology & carcinogenesis Immunotherapy business Lenvatinib medicine.drug
Zdroj:	Asia-Pacific journal of clinical oncologyREFERENCES. 15
ISSN:	1743-7563
Popis:	Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab3311ece4fcad44b08a9840523471f1 https://pubmed.ncbi.nlm.nih.gov/31762165 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.